Figure 3From: Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular riskEvent rates for serious gastrointestinal and cardiovascular events for each coxib, and for all coxibs combined, for 1000 patients treated for one year with each drug.Back to article page